A 30-Year-Old Man with an Unusually Large Untreated Plantar Fibrolipoma That Disrupted Ambulation and Required Operative Excision.

J Am Podiatr Med Assoc

‡Non-Surgical Foot and Ankle Service, Joe DiMaggio Heel Pain Center, Hospital for Special Surgery, NY, NY; Yale School of Public Health, New Haven CT.

Published: October 2022

A 30-year-old man working as a waiter presented with a progressively enlarging and symptomatic soft-tissue mass on the plantar medial aspect of his left foot. The mass was painful and disrupting ambulation, despite footwear modifications. He ultimately underwent excision of what was a determined to be a fibrolipoma, returning to his regular shoes and all activities. Plantar neoplasms, even when benign, can grow to sizes that can result in significant disability. If left untreated, particularly in individuals engaged in occupations requiring frequent standing or walking, excision of the mass will often require a more aggressive operative approach.

Download full-text PDF

Source
http://dx.doi.org/10.7547/21-019DOI Listing

Publication Analysis

Top Keywords

30-year-old man
8
man unusually
4
unusually large
4
large untreated
4
untreated plantar
4
plantar fibrolipoma
4
fibrolipoma disrupted
4
disrupted ambulation
4
ambulation required
4
required operative
4

Similar Publications

Background: Anaplastic lymphoma kinase (ALK)-rearranged renal cell carcinoma (ALK-RCC) is a rare molecularly defined tumor entity included in the fifth edition of the World Health Organization Classification of Tumors. It is characterized by rearrangement of the ALK gene with various fusion partner genes, which most commonly results in oncogenic fusion proteins leading to ALK activation.

Case Presentation: A 30-year-old Chinese man underwent partial nephrectomy for a left renal tumor measuring 5 cm in diameter.

View Article and Find Full Text PDF

Diagnosing Late-Onset Tay-Sachs Through Next Generation Sequencing and Functional Enzyme Testing: From Genes to Enzymes.

Neurol Genet

December 2024

From the School of Medicine (A.R.T., J.R.), The University of Queensland; Department of Neurology (W.R., P.A.M., R.D.H., L.V.), Royal Brisbane & Women's Hospital; The University of Queensland (P.A.M., R.D.H., L.V.), UQ Centre for Clinical Research; and Genetic Health Queensland (J.R.), Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia.

Tay-Sachs disease is a neurodegenerative disorder characterized by progressive neurologic impairment due to pathogenic variants in the gene that codes for the alpha subunit of β-hexosaminidase. We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman. Both patients had compound heterozygosity in the gene with 4 distinct variants.

View Article and Find Full Text PDF

A 30-year-old man with a 5-month history of lumbar pain was hospitalized due to worsening pain and restricted mobility. CT and MRI scans indicated multiple vertebral destructions, prompting further assessment with 18F-FDG PET/CT. PET/CT imaging showed widespread and avid 18F-FDG uptake in the bones, mainly in the vertebrae.

View Article and Find Full Text PDF

The guidelines from the European and American Societies for Gastrointestinal Endoscopy discourage endoscopic retrieval of drug bags in body stuffers. However, recent evidence challenges this stance, demonstrating successful bag retrieval without fatal outcomes. We present two distinct cases illustrating varying outcomes of intervention.

View Article and Find Full Text PDF

Long-acting injectable formulation of cabotegravir/rilpivirine (CAB/RPV) is a promising novel maintenance therapy for HIV infection. However, coinfection with active hepatitis B virus (HBV) infection is a contraindication to initiating this therapy. Despite guidelines, patients with HBV immunity can still contract acute HBV infection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!